• BCECF in Microenvironmental pH Regulation: Principles to Pre

  2026-07-08

  Explore how BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) enables advanced, quantitative analysis of extracellular pH microenvironments in biomedical research. This in-depth guide reveals unique methodological insights and practical assay strategies distinct from existing resources.

• Bleomycin Sulfate: Protocols and Pitfalls for Pulmonary Fibr

  2026-07-08

  Bleomycin Sulfate is a DNA strand break inducer widely used to model chemotherapy-induced DNA damage and pulmonary fibrosis, especially for mechanistic studies involving TGF-β/Smad and JAK-STAT signaling pathways. This article details protocol parameters, solubility considerations, and workflow best practices to optimize reproducibility in both in vitro and in vivo settings. Avoid use where precise long-term solution stability or ethanol solubility is required.

• Bromodomain Inhibitor (+)-JQ1: Multi-Pathway Modulation & Pr

  2026-07-07

  Explore the multi-dimensional impact of Bromodomain Inhibitor, (+)-JQ1 on chromatin regulation, apoptosis, and cytokine storm modulation. This article uniquely integrates mechanistic insights, protocol parameters, and assay guidance for advanced BET bromodomain inhibitor research.

• Amitriptyline HCl in High-Throughput BBB & Neuropharmacology

  2026-07-07

  Amitriptyline HCl empowers rigorous in vitro blood-brain barrier (BBB) and receptor modulation assays, enabling nuanced CNS drug discovery workflows. This workflow-focused review highlights key innovations, protocol optimizations, and troubleshooting strategies to maximize translational impact with this APExBIO tricyclic research compound.

• Dasatinib (BMS-354825): Optimizing Kinase Assays in Cancer M

  2026-07-06

  Dasatinib (BMS-354825) unlocks precise, multi-kinase targeting for advanced oncology workflows, enabling researchers to dissect Src and Bcr-Abl signaling in both cellular and animal systems. Leveraging recent breakthroughs in EMT and stemness mechanisms, this guide translates cutting-edge insights into robust experimental protocols and troubleshooting strategies.

• Macrophage-Derived EV miR-660 Drives Breast Cancer Metastasi

  2026-07-06

  This study uncovers how tumor-associated macrophage (TAM)-derived extracellular vesicles (EVs) transfer microRNA-660 to breast cancer cells, promoting metastasis via suppression of KLHL21 and activation of the IKKβ/NF-κB p65 pathway. The findings highlight a critical non-cell-autonomous mechanism in breast cancer progression and suggest new avenues for targeting TAM-EV-miRNA interactions.

• Sex Differences in Cannabinoid Withdrawal Revealed by WIN 55

  2026-07-05

  Brewer et al. systematically investigated somatic and anxiety-like withdrawal behaviors in male and female rats following exposure to the synthetic cannabinoid agonist WIN 55,212-2. Their findings uncover distinct sex-specific behavioral signatures during withdrawal, with implications for endocannabinoid system modulator research and preclinical modeling of cannabinoid dependence.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Tumo

  2026-07-04

  This article reviews the preclinical characterization of anlotinib hydrochloride as a highly potent and selective vascular endothelial growth factor receptor-2 (VEGFR2) inhibitor. The study establishes its robust anti-angiogenic mechanism, strong selectivity profile, and in vivo efficacy, providing a foundation for its use in cancer research and translational workflows.

• Reliable CaMKII Inhibition with KN-62, 1-[N,O-bis-(5-isoquin

  2026-07-03

  This article addresses common laboratory challenges in cell signaling and proliferation assays, demonstrating how KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine (SKU A8180) delivers selective, reproducible inhibition of CaMKII for robust experimental outcomes. Grounded in literature and vendor transparency, it provides evidence-driven guidance on protocol design, data interpretation, and product selection for biomedical researchers.

• AR Heterogeneity Drives Divergent Prostate Cancer Therapy Re

  2026-07-03

  This study reveals that androgen receptor (AR) expression in prostate cancer is highly heterogeneous, delineating distinct cellular subtypes with different responses to castration and enzalutamide. By modeling AR+/hi and AR−/lo clones, the research provides evidence for tailored therapeutic strategies and highlights BCL-2 as a promising target in resistant disease.

• Podophyllotoxin in HCC: Mechanistic Insights and Experimenta

  2026-07-02

  Explore how Podophyllotoxin, a key cell cycle arrest agent, advances hepatocellular carcinoma (HCC) research. This article delivers unique, protocol-driven insights and comparative analysis to optimize your assays.

• FLT3–TAZ Axis Drives Drug Resistance in Blast Phase CML

  2026-07-02

  Shin et al. reveal that aberrant FLT3 signaling, via JAK–STAT3–TAZ–TEAD–CD36, underlies drug resistance and poor prognosis in blast phase chronic myeloid leukemia (BP-CML). The study leverages multi-omics and patient-derived models to propose FLT3 as both a prognostic marker and therapeutic target, advancing strategies for overcoming tyrosine kinase inhibitor resistance.

• MK-4827 (Niraparib): Optimizing PARP Inhibition in Cancer Re

  2026-07-01

  MK-4827 (Niraparib) from APExBIO enables precise and potent PARP-1/-2 inhibition, accelerating BRCA-mutant and combination strategy cancer research. Recent studies reveal that hyperthermia-induced modulation of DNA repair enhances its impact even in BRCA2-proficient models, providing a new dimension to experimental design.

• Asunaprevir (BMS-650032): Strategic Horizons in HCV Research

  2026-07-01

  This thought-leadership article explores the mechanistic, translational, and strategic value of Asunaprevir (BMS-650032) for hepatitis C virus research. We dissect its structure-function insights, experimental best practices, and competitive edge, while bridging recent advances in chromatin-targeted oncology as a conceptual lens for next-generation antiviral strategies. This piece advances the discussion beyond standard protocols, offering actionable guidance for translational scientists and research leaders.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 to Mitigate CI-AKI

  2026-06-30

  This study demonstrates that activation of the FXR-KLF11 transcriptional axis protects against contrast-induced acute kidney injury (CI-AKI) by suppressing the pro-inflammatory and pro-apoptotic JAK2/STAT3 pathway. These mechanistic insights highlight novel preventive strategies for CI-AKI, particularly in high-risk cardiovascular models.

14677 records 1/979 page Next 12345 下5页 Last page